Table 1.
Insulin—generic name | Strength | Delivery | |||
---|---|---|---|---|---|
Concentrated A | 100 u/mL | Vial | Disposable pen | Reusable pen | |
Basal insulin | |||||
Long-acting | |||||
Insulin degludec | + | + | + | ||
Insulin Degludec/liraglutide | + | + | |||
Insulin detemir | + | + | + | ||
Insulin glargine | + | + | + | + | + |
Insulin glargine/lixisenatide | + | + | |||
Intermediate-acting | |||||
Insulin human isophane (NPH) | + | + | + | + | |
Short/rapid insulin | |||||
Short-acting | |||||
Insulin human regular | + | + | + | + | + |
Rapid-acting | |||||
Insulin aspart | + | + | + | + | |
Insulin glulisine | + | + | + | + | |
Insulin lispro | + | + | + | + | + |
Pre-mix insulin | |||||
Insulin aspart protamine/insulin aspart | + | + | + | + | |
Insulin human isophane (NPH)/Insulin human regular | + | + | + | + | |
Insulin lispro protamine/insulin lispro | + | + | + |
This analysis excludes any use of Insulin Human Zinc (Lente), Insulin Human Zinc, Extended (Ultralente) and Insulin, Human Inhaled.
Concentrated insulin includes 200, 300 and 500 u/mL.